Boston Life Sciences Announces Submission Of NDA Amendment For THERAFECTIN.BOSTON--(BUSINESS WIRE)--July 1, 1998--Boston Life Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BLSI BLSI Boston Life Sciences, Inc. ) announced that it had submitted an amendment to the pending NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any for THERAFECTIN(R). The amendment is comprised of the results of the Company's Phase III trial of THERAFECTIN as well as the manufacturing data pertaining to the clinical supplies used in the study. The results of the trial had previously been summarized in a January 20, 1998 Company Press Release. The Company has requested marketing approval based on the results of the trial and the previous data contained in the THERAFECTIN NDA. THERAFECTIN is a carbohydrate-based small molecule that has been developed as an oral treatment of Rheumatoid Arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . "We believe, based on its favorable safety profile and convenient oral dosing, that THERAFECTIN, if approved would receive significant market acceptance," said Marc Lanser MD, Chief Scientific Officer at BLSI. BLSI is developing novel treatments for cancer, autoimmune diseases, andcentral nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . In addition to THERAFECTIN, products in clinical trials or in preclinical development by BLSI include Troponin I, a naturally-occurring anti-angiogenesis factor for the potential treatment of solid tumors; AF1 for the potential treatment of stroke and spinal cord injury Spinal Cord Injury Definition Spinal cord injury is damage to the spinal cord that causes loss of sensation and motor control. Description Approximately 10,000 new spinal cord injuries (SCIs) occur each year in the United States. ; Altropane, a radioimaging agent for the diagnosis of Parkinson's Disease and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. This press release contains certain forward-looking statements regarding market prospects for THERAFECTIN. Actual results may vary materially, and there can be no assurance that regulatory approval will be obtained, or that if obtained, that THERAFECTIN will receive significant market acceptance. For additional information contact: David Hillson President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. 617/425-0200
CONTACT: MARTIN E. JANIS & CO., Chicago
Bev Jedynak, 312/943-1100
or
David Hillson
President and CEO
617/425-0200
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion